Vitality Watch

⚠ Evidence note: Most trends in this area rest on anecdote and mechanism; where real evidence exists it is usually for narrower claims than the trend makes.

Mentioned 1× · first seen 13-sep-2026 · last seen 13-sep-2026

Low-Dose Rapamycin for Longevity

Current understanding

Low-dose weekly or daily rapamycin (typically 1–6 mg) is one of the most-discussed off-label longevity protocols, promoted by clinicians and biohackers on the basis of mTOR-inhibition lifespan effects in mice [animal-model] and a growing but still small human-trial base [human-observational / early human-rct]. A 2026 pilot single-arm trial (1 mg/day × 4 weeks) reported >15% increases in cerebral blood flow plus metabolic and inflammatory shifts specifically in middle-aged APOE4 carriers, with minimal CBF change in non-carriers [human-observational, pilot, uncontrolled], extending the trend into genotype-stratified cerebrovascular endpoints. Trend momentum runs well ahead of controlled outcome data.

Evidence log

Open questions

Related

Contributing findings

pubmed trial early
EXPRESS: Rapamycin increases cerebral blood flow and modulates metabolic, inflammatory, and microbiome profiles in healthy middle-aged APOE4 carriers: a pilot single-arm trial.
10-sep-2026 novelty 3 per-area 3 introduces

build build 880 · 2bcef25 · 2026-11-18